HOME > ARCHIVE
ARCHIVE
- Shionogi: Restructuring Affects Sales, Net Profits
June 2, 2003
- Pfizer to Introduce 8-Sector, 13-Team System: President Bootes
June 2, 2003
- Chugai: Merger Drives It to 4th Position in Japan
June 2, 2003
- Purdue to Market Meiji Seika's Meiact in North America
June 2, 2003
- Banyu: Nu-lotan Drives Sales to \185.4 Bil.
June 2, 2003
- Over 40% of Leading Makers Hired Over 100 New Employees in April: Survey
June 2, 2003
- Tanabe Seiyaku: Sales Down 3.9% Due to Business Reorganization
June 2, 2003
- BUSINESS NEWS IN BRIEF
June 2, 2003
- Dainippon: "Dear-Doctor" Letter for Gatiflo Hurts Sales
June 2, 2003
- NEW PRODUCTS
June 2, 2003
- Ono: Sales Up 1.2% Despite NHI Price Revision
June 2, 2003
- 11 New Drugs Including Xeloda to Enter NHI Price List
June 2, 2003
- Kyorin: 4th Straight Year of Record Sales
June 2, 2003
- REGULATORY NEWS IN BRIEF
June 2, 2003
- Mochida: Slight Sales Increase Despite Above-average NHI Price Cut
June 2, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
June 2, 2003
- Zeria: Sales Show Modest 2.3% Increase
June 2, 2003
- DIAGNOSTICS NEWS IN BRIEF
June 2, 2003
- Torii: Sales, Profits Plummet
June 2, 2003
- Takeda: Sales, Profits Increase for 12th, 11th Consective Years Respectively
June 2, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
